FDA Inspection 1230625 — Novartis D.O.O.
The FDA completed an inspection of Novartis D.O.O. on Jan 25, 2023 in Ljubljana. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 25, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ljubljana (Slovenia)
Additional Details
Mutual Recognition Agreement (MRA)